Myriad Genetics advances Alzheimer's drug candidates

Myriad Genetics Reports Financial Results for Fiscal 2004: "Progress in the Company's drug development programs included the completion of a Phase I clinical trial in Alzheimer's disease...(and) the completion of enrollment of a Phase II trial in Alzheimer'ss disease."